Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05931601
Other study ID # OP_1749
Secondary ID 2023-504584-16-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 8, 2023
Est. completion date January 31, 2026

Study information

Verified date June 2024
Source Odense University Hospital
Contact Lasse P Bentsen, MD
Phone +4520496950
Email lasse.paludan.bentsen@rsyd.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this pragmatic, multi-center, superiority, randomized clinical trial is to compare early treatment with peripheral (through a vein) infused noradrenaline (a natural hormone that increases blood pressure) with fluid only therapy in patients with hypotensive and shock in the Danish Emergency Departments (ED). The main questions it aims to answer are: If early initiated noradrenaline in non-bleeding hypotensive patients presenting in the ED can - Improve time to shock control. - Reduce the need for ICU admittance. - Decrease mortality. Participants will be included by the clinical staff and treated urgently with either noradrenaline or usual treatment during their Emergency Department stay. After completion of the treatment in the Emergency Department, patient data will be extracted from the bed-side measurements, electronic health records and national registers. Patients will be contacted by the research staff 1 year after study inclusion to answer brief questions about their daily physical function and ability to care for themselves. Researchers will compare with patients receiving fluid therapy only, as this is the usual standard of care in Danish Emergency Departments.


Description:

Please refer to the full protocol.


Recruitment information / eligibility

Status Recruiting
Enrollment 320
Est. completion date January 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years of age - Signs or suspicion of hypotension or shock (of any type such as septic, vasodilatory or hypovolemic not included in the exclusion criteria) defined as: 1. SBP < 100mmHg or MAP < 65 mmHg combined with lactate > 2.0 mmol/L, 2. Physician defined blood pressure for the individual patient combined with a lactate > 2.0 mmol/L 3. Either SBP < 100mmHg or MAP < 65mmHg with obvious signs of shock with any lactate level evaluated by either two non-specialist physicians (e.g. registrar medical doctors) or a specialist physician. - Received at least 500ml of intravenous fluid before study inclusion (Including prehospital administration) within the first 4 hours of ED arrival. - Clinical Frailty Score (CFS) of =4. If CFS is =5 and the treating physician find the patient suitable for ICU admittance, the participant can be enrolled, if the on-call ICU doctor would accept the patient for ICU admittance. If the treating physician is unsure of ICU eligibility, regardless of CFS score, the patient should be consulted with the ICU consultant before study inclusion. Exclusion Criteria: - Cardiogenic, anaphylactic, haemorrhagic, or neurogenic shock suspected by the treating physician. - Fertile women (<60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG or women breastfeeding. - Patient deemed terminally ill or with a severe co-morbid status resulting in non-eligibility for ICU admittance decided by either the treating physician or ICU consultant. - Known allergy to noradrenaline.

Study Design


Intervention

Drug:
Noradrenaline
See arm description

Locations

Country Name City State
Denmark Bispebjerg Hospital Copenhagen
Denmark Esbjerg Hospital Esbjerg
Denmark Gødstrup Regional Hospital Herning
Denmark Zealand University Hospital Køge
Denmark Odense University Hospital Odense

Sponsors (1)

Lead Sponsor Collaborator
Odense University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Proportion of patients receiving vasopressor at any point within 24 hours Bed-side assessment during treatment and registered in the case report form or by extraction from the patient's electronic medical record. At 24 hours
Other Time to vasopressor initiation Bed-side assessment during treatment and registered in the case report form or by extraction from the patient's electronic medical record. At 30 days
Other Hours of vasopressor infusion Bed-side assessment during treatment and registered in the case report form or by extraction from the patient's electronic medical record. At 30 days
Other Proportion of patients with pulmonary oedema within 72 hours Bed-side assessment during treatment and registered in the case report form or by extraction from the patient's electronic medical record. At 72 hours
Other Proportion of patients with acute kidney failure within 72 hours Bed-side assessment during treatment and registered in the case report form or by extraction from the patient's electronic medical record. At 72 hours
Other Proportion of patients admitted to the ICU Data is extracted from the patient's electronic medical records. At 30 days
Other ED Length of stay Data is extracted from the patient's electronic medical records. At 72 hours
Other ICU length of stay Data is extracted from the patient's electronic medical records. At 30 days
Other Hospital length of stay Data is extracted from the patient's electronic medical records. At 30 days
Other Proportion and duration of mechanical ventilation Data is extracted from the patient's electronic medical records. At 30 days
Other Proportion and length of renal replacement therapy Data is extracted from the patient's electronic medical records. At 30 days
Other Amount of fluid therapy within the first 24 hours Bed-side assessment during treatment and registered in the case report form or by extraction from the patient's electronic medical record. At 24 hours
Other Proportion of serious adverse events for noradrenaline or fluid therapy, e.g. extravasation or overdosis of noradrenaline, pulmonary edema, new cardiac arrhytmias, during the intervention of control period Bed-side assessment during treatment and registered in the case report form or by extraction from the patient's electronic medical record. At 24 hours
Primary The primary outcome is the proportion of patients achieving either SBP >100 mmHg or MAP > 65 mmHg or a target blood pressure set by the treating physician at 90 (±15) minutes after inclusion. Bed-side assessment during treatment and registered in the case report form. At 90 minutes
Secondary Number of intensive care unit (ICU) free days alive within 30 days Data is extracted from the Danish national registries or the patient's electronic medical record. At 30 days
Secondary Time without shock within 24 hours Bed-side assessment during treatment and registered in the case report form or by extraction from the patient's electronic medical record. At 24 hours
Secondary 30-day all-cause mortality Data is extracted from the Danish national registries or the patient's electronic medical records. At 30 days
Secondary In-hospital all-cause mortality Data is extracted from the Danish national registries or the patient's electronic medical records. At hospital discharge, an average of 30 days efter inclusion
See also
  Status Clinical Trial Phase
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Active, not recruiting NCT02016599 - Effects of Transitional Circulation in ELBW Infants
Recruiting NCT05836610 - Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates Phase 4
Completed NCT02907931 - Carotid Doppler Ultrasound for the Measurement of Intravascular Volume Status N/A
Completed NCT03215797 - Phenylephrine or Norepinephrine for a Better Hemodynamic Stability Phase 3
Suspended NCT02315937 - Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography' N/A
Recruiting NCT02532270 - Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring N/A
Completed NCT02437799 - Dicrotic Notch and Hypotension at Caesarean Under Spinal Anaesthesia N/A
Completed NCT02802683 - Hemodynamic Impact of Hyperbaric Versus Isobaric for Spinal Anesthesia During Cesarean Delivery Phase 4
Completed NCT02146898 - The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery N/A
Not yet recruiting NCT01941472 - Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness N/A
Completed NCT01930227 - Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hypotension After Spinal Anesthesia in Parturients N/A
Recruiting NCT01434251 - Treatment of Hypotension of Prematurity (TOHOP) N/A
Completed NCT01592669 - Passive Leg Raising Attenuates and Delays Tourniquet Deflation-induced Hypotension and Tachycardia N/A
Withdrawn NCT01183741 - Accuracy of Non-Invasive Blood Pressure Measurement in Adults Phase 3
Completed NCT00991627 - Different Approaches to Maternal Hypotension During Cesarean Section Phase 4
Withdrawn NCT00750516 - Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet
Completed NCT00115726 - Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure Phase 4
Recruiting NCT05513066 - Management Arterial Hypotension During Planned Caesarean Section, Intravenous Ephedrine/Phenylephrine Mixture Versus Intravenous Baby Noradrenaline
Completed NCT04089644 - Manual vs Closed-loop Control of Mean Arterial Pressure N/A